IPCIF - Intellipharmaceutics International Inc.
| Previous Close | 0.1520 |
| Open | 0.1643 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 0.1515 - 0.2031 |
| 52 Week Range | 0.0900 - 0.4300 |
| Volume | 250,343 |
| Avg. Volume | 84,421 |
| Market Cap | 4.315M |
| Beta (3Y Monthly) | 3.00 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.5910 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- ACCESSWIRE
Intellipharmaceutics Announces FDA Advisory Committee Meeting for Aximris XR(TM) (Oxycodone Hydrochloride extended release), an Abuse Deterrent Opioid Analgesic for the Treatment of Moderate to Severe Pain
TORONTO, ON / ACCESSWIRE / December 5, 2019 / Intellipharmaceutics International Inc. (OTCQB:IPCIF and TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, announced today that a joint meeting of the Anesthetic and Analgesic Drug Products Advisory Committee and Drug Safety and Risk Management Advisory Committee of the U.S. Food and Drug Administration ("FDA") has been scheduled for January 15, 2020 to review the Company's New Drug Application ("NDA") for Aximris XRTM abuse-deterrent oxycodone hydrochloride extended-release tablets. The original NDA was accepted for filing by the FDA on February 2, 2017.
- ACCESSWIRE
Intellipharmaceutics Signs an Exclusive License and Commercial Supply Agreement with Tris Pharma, Inc. for Venlafaxine ER
TORONTO, ON / ACCESSWIRE / November 25, 2019 / Intellipharmaceutics International Inc. (OTCQB:IPCIF and TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, announced today that it has entered into a license and commercial supply agreement with Tris Pharma, Inc. ("Tris"), by which the Company has granted Tris an exclusive license to market, sell and distribute in the United States, Venlafaxine ER in the 37.5, 75, and 150 mg strengths (the "licensed products") approved for sale in the US market by the U.S. Food and Drug Administration ("FDA"). Several other generic versions of the licensed products are currently available in the market.
- ACCESSWIRE
Intellipharmaceutics Closes USD$250,000 Convertible Debenture Financing with Drs. Isa and Amina Odidi
TORONTO, ON / ACCESSWIRE / November 18, 2019 / Intellipharmaceutics International Inc. (OTCQB:IPCIF and TSX:IPCI) ("Intellipharmaceutics" or the "Company") and Drs. Isa and Amina Odidi announce that, following the close of markets on November 15, 2019, the Company issued to Drs. Isa and Amina Odidi, by way of private placement, an unsecured convertible debenture of the Company in consideration for, and in the aggregate principal amount of, USD$250,000 (the "Debenture"). The principal amount owing under the Debenture is convertible at any time and from time to time into common shares in the capital of the Company (the "Common Shares") at a conversion price equal to USD$0.12 per Common Share.
- ACCESSWIRE
Intellipharmaceutics Announces Settlement Agreement in Class Action Lawsuit, Which is Subject to Court Approval
The settlement is subject to the approval of the court following notice to class members. The stipulation of settlement provides for a settlement payment of US$1.6 million, which Intellipharmaceutics anticipates will be funded by available insurance.
- ACCESSWIRE
Intellipharmaceutics Update on its Oxycodone ER New Drug Application
TORONTO, ON / ACCESSWIRE / October 24, 2019 / Intellipharmaceutics International Inc. (OTCQB:IPCIF and TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, announced today that it has been advised by the U.S. Food and Drug Administration ("FDA") that product specific advisory committee meetings for opioid analgesics, as related to Intellipharmaceutics' Oxycodone ER New Drug Application ("NDA"), which were previously postponed, as announced on July 24, 2019, are no longer on hold. The Company is pleased with this development and is prepared to attend any advisory committee meetings in the future.
- ACCESSWIRE
Intellipharmaceutics Announces Third Quarter 2019 Results
TORONTO, ON / ACCESSWIRE / October 11, 2019 / Intellipharmaceutics International Inc. (OTCQB:IPCIF) and (TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company ...
- ACCESSWIRE
Intellipharmaceutics Announces an Update in the Purdue Litigation
TORONTO, ONTARIO / ACCESSWIRE / October 4, 2019 / Intellipharmaceutics International Inc. (IPCIF)(IPCI.TO) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, announced today that following the filing of a bankruptcy stay by Purdue Pharma L.P., the Company's ongoing litigation cases, number 1:17-cv-00392-RGA and 1:18-cv-00404-RGA-SRF between Purdue Pharma L.P. et al and Intellipharmaceutics, have been stayed and the existing trial dates in both cases have been vacated by orders issued in each case by the judge in the District of Delaware on October 3, 2019. The Company and its management intend to continue to vigorously defend against the claims of patent infringement made by Purdue Pharma L.P. in the above cases.
- ACCESSWIRE
Intellipharmaceutics Signs a Second Exclusive License and Commercial Supply Agreement with Tris Pharma, Inc.
TORONTO, ON / ACCESSWIRE / September 5, 2019 / Intellipharmaceutics International Inc. (IPCIF) and (IPCI.TO) (“Intellipharmaceutics” or the “Company”), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, announced today that it has entered into a license and commercial supply agreement with Tris Pharma, Inc. ("Tris"), by which the Company has granted Tris an exclusive license to market, sell and distribute in the United States, Desvenlafaxine Succinate ER in the 50 and 100 mg strengths (the "licensed products") approved for sale in the U.S. market by the U.S. Food and Drug Administration ("FDA"). Several other generic versions of the licensed products are currently available in the market.
- ACCESSWIRE
Intellipharmaceutics Signs an Exclusive License and Commercial Supply Agreement with Tris Pharma, Inc.
TORONTO, ON / ACCESSWIRE / August 15, 2019 / Intellipharmaceutics International Inc. (OTCQB:IPCIF and TSX:IPCI) (“Intellipharmaceutics” or the “Company”), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, announced today that it has entered into a license and commercial supply agreement with Tris Pharma, Inc. ("Tris"), by which the Company has granted Tris an exclusive license to market, sell and distribute in the United States, Quetiapine ER in the 50, 150, 200, 300 and 400 mg strengths (the "licensed products") approved for sale in the US market by the U.S. Food and Drug Administration ("FDA"). Several other generic versions of the licensed products are currently available in the market.
- ACCESSWIRE
Intellipharmaceutics International Inc. Announces Update on its Oxycodone ER New Drug Application
TORONTO, ON / ACCESSWIRE / July 24, 2019 / Intellipharmaceutics International Inc. (OTCQB: IPCIF and TSX: IPCI) ("Intellipharmaceutics" or the "Company,") a pharmaceutical company specializing ...
- ACCESSWIRE
Intellipharmaceutics Announces Second Quarter 2019 Results
TORONTO, ON / ACCESSWIRE / July 10, 2019 / Intellipharmaceutics International Inc. (OTCQB: IPCIF and TSX: IPCI) (“Intellipharmaceutics” or the “Company”), a pharmaceutical company specializing in the research, ...
- ACCESSWIRE
Intellipharmaceutics International Inc. Announces $10,000,000 Equity Financing Commitment
TORONTO, ON / ACCESSWIRE / July 8, 2019 / Intellipharmaceutics International Inc. (OTCQB: IPCIF and TSX: IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, announced today that it has obtained an equity financing commitment of up to $10,000,000 from Silverback Capital Corporation, a private investment firm ("Silverback Capital"). During the 36-month term of the equity financing commitment, Intellipharmaceutics may sell shares of its common stock to Silverback Capital up to the $10,000,000 total commitment at a 25% discount to the volume weighted average price of the Company’s common stock for the 5 trading days prior to the date the Company provides notice to Silverback Capital, or if the maximum discount rate allowed by the Company’s principal exchange is less than 25%, then the maximum discount rate allowed.
- ACCESSWIRE
Intellipharmaceutics Announces Receipt of Cannabis Drug License from Health Canada
TORONTO, ON / ACCESSWIRE / May 30, 2019 / Intellipharmaceutics International Inc. (OTCQB: IPCIF and TSX: IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that the Company's pre-existing license to conduct activities with Cannabidiol ("CBD") has been migrated by Health Canada to a Cannabis Drug License ("CDL") under the Cannabis Regulations. Intellipharmaceutics' new CDL allows the Company to continue to possess cannabis, produce a drug containing cannabis and sell a drug containing cannabis in Canada.
- ACCESSWIRE
Intellipharmaceutics Reports Director Election Results
TORONTO, ON / ACCESSWIRE / May 29, 2019 / Intellipharmaceutics International Inc. (OTCQB: IPCIF and TSX: IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing ...
- ACCESSWIRE
Intellipharmaceutics to present at the 9th Annual LD Micro Invitational
TORONTO, ON / ACCESSWIRE / May 29, 2019 / Intellipharmaceutics International Inc. (OTCQB: IPCIF and TSX: IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, announced today that it will be presenting at the 9th annual LD Micro Invitational on Tuesday June 4th, 2019 at 2:20pm PST. Executive Greg Powell, CFO will be presenting and meeting with investors. Intellipharmaceutics International Inc. is a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs.
- ACCESSWIRE
Intellipharmaceutics Announces FDA Approval for Generic Pristiq(R)
TORONTO, ON / ACCESSWIRE / May 10, 2019 / Intellipharmaceutics International Inc. (OTCQB: IPCIF and TSX: IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, announced today that it has received approval from the U.S. Food and Drug Administration ("FDA") for the Company's abbreviated new drug application ("ANDA") for desvenlafaxine extended-release tablets in the 50 and 100 mg strengths. The approved product is a generic equivalent of the branded product Pristiq®.
- ACCESSWIRE
Intellipharmaceutics Closes US$1.05 Million Convertible Debenture Financing with Drs. Isa and Amina Odidi
TORONTO, ON / ACCESSWIRE / May 7, 2019 / Intellipharmaceutics International Inc. (OTCQB: IPCIF and TSX: IPCI) ("Intellipharmaceutics" or the "Company") and Drs. Isa and Amina Odidi announce that, following the close of markets on May 1, 2019, the Company issued to Drs. Isa and Amina Odidi, by way of private placement, an unsecured convertible debenture of the Company in consideration for, and in the aggregate principal amount of, USD$1,050,000 (the "Debenture"). The principal amount owing under the Debenture is convertible at any time and from time to time into common shares in the capital of the Company (the "Common Shares") at a conversion price equal to USD$0.59 per Common Share.
- ACCESSWIRE
Intellipharmaceutics Announces First Quarter 2019 Results
TORONTO, ON / ACCESSWIRE / April 15, 2019 / Intellipharmaceutics International Inc. (OTCQB: IPCIF and TSX: IPCI) (''Intellipharmaceutics'' or the ''Company''), a pharmaceutical company specializing in ...
- ACCESSWIRE
U.S. FDA Acknowledges Receipt of Intellipharmaceutics' Resubmission of Oxycodone ER New Drug Application, Deems it a Complete Response, and Designates August 28, 2019 as Goal Date for Review
TORONTO, ON / ACCESSWIRE / March 29, 2019 / Intellipharmaceutics International Inc. (OTCQB: IPCIF and TSX: IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company ...